FDA OKs Bone Drug to Prevent Fracture in Certain Cancer Patients (HealthDay)

HealthDay – MONDAY, Sept. 19 (HealthDay News) — The U.S. Food and Drug
Administration has expanded approval for the Amgen bone-building drug
Prolia (denosumab) to include prostate cancer or breast cancer patients
who are taking certain hormonal therapies.